Project Grant R01HL180540
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $577K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06511, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $1.6 million under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate GA12-dependent mechanisms of basal and regulated endothelial cell von Willebrand factor (VWF) secretion. This is a Project Grant (R01HL186410). The research addresses microvascular thrombotic occlusions in inflammatory conditions such as sepsis and sickle cell disease, where elevated VWF plasma levels...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $835,583 under Project Grant R01HL188033 on September 1, 2026, through the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into von Willebrand factor as a driver of trauma-induced thromboinflammation. The project investigates how traumatic injury triggers pathological modifications of von Willebrand factor that propagate neutrophil interactions, netosis, and microvascular...
- The National Heart, Lung, and Blood Institute awarded Yale University $838,491 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify novel gene variants that drive endothelial cell activation during atherosclerotic cardiovascular disease. The recipient will elucidate mechanisms by which gain-of-function defects in ZFYVE21, an endosome-associated protein highly expressed in endothelial cells, contribute to endothelial cell activation and exacerbate...
- The National Institute on Aging awarded the University of Texas Health Science Center at Houston $650,533 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the contribution of intramural von Willebrand factor (VWF) to cerebrovascular dysfunction in amyloidosis. The research examines how VWF, a protein produced in endothelial cells and megakaryocytes, accumulates abnormally within blood vessel walls and contributes to vascular pathology in conditions including...
- The National Heart Lung and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded $743,131 to the University of Wisconsin - Madison on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory mechanisms of the vessel wall in deep vein thrombosis. The research addresses thrombospondin-1 (TSP1), a matricellular protein upregulated in endothelial cells during DVT. The project tests...
- The National Heart, Lung, and Blood Institute awarded Worcester Polytechnic Institute $532,935 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the endothelial glycocalyx in sepsis-induced coagulopathy. The research targets sepsis-associated coagulopathy, a condition characterized by uncontrolled thrombosis, large vessel occlusion, and stroke that resists traditional anticoagulation therapies. The project will examine how sepsis...
- The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $1,626,320 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to study thrombotic disorders linked by ADAMTS13 deficiency. The research investigates the metalloprotease ADAMTS13, which cleaves ultra-large von Willebrand factor multimers into smaller units and regulates the thrombogenicity of this circulating coagulation factor. The project focuses on immune...
- The National Heart, Lung, and Blood Institute awarded New York University $836,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial mechanosensing of circulatory flow in health and disease. The project will examine how endothelial cells lining blood and lymphatic vessels respond to fluid flow forces, with focus on the roles of PLXND1 (a transmembrane semaphorin receptor) and KLF2 (a transcription factor) in endothelial responses to...
- The National Heart, Lung, and Blood Institute awarded Yale University $1.68 million under the Cardiovascular Diseases Research program (CFDA 93.837) on July 1, 2026, to investigate developmental mechanisms driving vascular resiliency in the brain's Circle of Willis. The funded research uses zebrafish and human induced pluripotent stem cell vascular organoids to uncover how loss of the microRNA mir-125a impairs embryonic brain angiogenesis and leads to incomplete Circle of Willis formation with...
- The National Heart, Lung and Blood Institute awarded the University of Washington $1,601,223 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to combine large-scale experiments and computational modeling to dissect how variants in the F9 gene affect coagulation factor IX (FIX) secretion, carboxylation, activation, and disease pathogenesis. The research addresses the clinical challenge of interpreting variants of uncertain significance (VUS) in hemophilia B...